• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艰难梭菌相关性感染:一种严重程度不一的疾病。

Clostridium difficile-associated infection: a disease of varying severity.

机构信息

Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198-3280, USA.

出版信息

Am J Surg. 2012 Dec;204(6):836-42. doi: 10.1016/j.amjsurg.2012.05.025. Epub 2012 Oct 1.

DOI:10.1016/j.amjsurg.2012.05.025
PMID:23036604
Abstract

Clostridium difficile-associated infection (CDI) can have varying severity from asymptomatic carriage to fulminant colitis. Its incidence and virulence in North America are increasing. The increase in virulence is associated with emergence of the highly toxigenic North American pulsed field gel electrophoresis-1 strain. The major risk factor for CDI is exposure to antibiotics. Another major risk factor is hospitalization. The spectrum of CDI ranges from asymptomatic carriers to fulminant disease. Although asymptomatic carriers require no treatment, fulminant disease carries a substantial mortality regardless of management strategy.

摘要

艰难梭菌相关性感染(CDI)的严重程度从无症状携带到暴发性结肠炎不等。它在北美的发病率和毒力正在增加。毒力的增加与高度产毒的北美脉冲场凝胶电泳-1 株的出现有关。CDI 的主要危险因素是接触抗生素。另一个主要危险因素是住院治疗。CDI 的范围从无症状携带者到暴发性疾病。虽然无症状携带者不需要治疗,但无论管理策略如何,暴发性疾病都有很高的死亡率。

相似文献

1
Clostridium difficile-associated infection: a disease of varying severity.艰难梭菌相关性感染:一种严重程度不一的疾病。
Am J Surg. 2012 Dec;204(6):836-42. doi: 10.1016/j.amjsurg.2012.05.025. Epub 2012 Oct 1.
2
The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings.艰难梭菌感染在住院和门诊环境中的发病率和严重程度不断增加。
Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):409-16. doi: 10.1586/egh.10.48.
3
Clostridium difficile Infection in children.儿童艰难梭菌感染。
JAMA Pediatr. 2013 Jun;167(6):567-73. doi: 10.1001/jamapediatrics.2013.441.
4
Clostridium difficile-associated diarrhea and colitis.艰难梭菌相关性腹泻和结肠炎
Mayo Clin Proc. 2001 Jul;76(7):725-30. doi: 10.4065/76.7.725.
5
Minimizing the threat of C. difficile.将艰难梭菌的威胁降至最低。
Nurs Manage. 2000 Jun;31(6):32-7; quiz 37-8.
6
Clostridium difficile infection: a comprehensive review.艰难梭菌感染:全面综述。
Crit Rev Microbiol. 2011 Aug;37(3):178-87. doi: 10.3109/1040841X.2011.556598. Epub 2011 May 24.
7
Diagnosis and management of patients with Clostridium difficile-associated diarrhoea.艰难梭菌相关性腹泻患者的诊断与管理
Nurs Stand. 2007;21(46):49-56; quiz 58. doi: 10.7748/ns2007.07.21.46.49.c4589.
8
Clostridium difficile-associated diarrhea and colitis.艰难梭菌相关性腹泻和结肠炎
J Calif Dent Assoc. 1999 May;27(5):405-9, 411-3.
9
Clostridium difficile infection.艰难梭菌感染
Curr Probl Surg. 2013 Jul;50(7):302-37. doi: 10.1067/j.cpsurg.2013.02.004.
10
Current strategies for management of initial Clostridium difficile infection.目前针对初次艰难梭菌感染的治疗策略。
J Hosp Med. 2012 Mar;7 Suppl 3:S5-10. doi: 10.1002/jhm.1909.

引用本文的文献

1
Epidemiology of Clostridium (Clostridioides) difficile Infection in Southeast Asia.东南亚艰难梭菌感染的流行病学
Am J Trop Med Hyg. 2022 Aug 8;107(3):517-26. doi: 10.4269/ajtmh.21-1167.
2
Temporal Variations in Patterns of Strain Diversity and Antibiotic Resistance in Thailand.泰国菌株多样性和抗生素耐药性模式的时间变化
Antibiotics (Basel). 2021 Jun 13;10(6):714. doi: 10.3390/antibiotics10060714.
3
A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Infection in Pre-clinical Models.一种新型口服抗体疗法及其在临床前模型中预防感染的潜力。
Front Microbiol. 2020 Sep 22;11:578903. doi: 10.3389/fmicb.2020.578903. eCollection 2020.
4
Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship.肠道微生物群调节:对感染控制和抗菌药物管理的影响。
Adv Ther. 2020 Oct;37(10):4054-4067. doi: 10.1007/s12325-020-01458-z. Epub 2020 Aug 7.
5
Risk factors and treatment outcomes of severe Clostridioides difficile infection in Singapore.新加坡艰难梭菌感染严重患者的风险因素和治疗结果。
Sci Rep. 2019 Sep 17;9(1):13440. doi: 10.1038/s41598-019-49794-7.
6
Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study.住院患者艰难梭菌感染的长期临床结局:一项单中心研究
Intest Res. 2014 Oct;12(4):299-305. doi: 10.5217/ir.2014.12.4.299. Epub 2014 Oct 27.
7
An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.一种优化的合成DNA疫苗,编码艰难梭菌的毒素A和毒素B受体结合结构域,可在体内诱导保护性抗体反应。
Infect Immun. 2014 Oct;82(10):4080-91. doi: 10.1128/IAI.01950-14. Epub 2014 Jul 14.
8
Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.基于艰难梭菌毒素 A 和 B 的重组抗原,可引发强烈的毒素中和免疫应答。
Vaccine. 2014 Feb 3;32(6):700-5. doi: 10.1016/j.vaccine.2013.11.099. Epub 2013 Dec 14.
9
Clostridium difficile colitis in patients undergoing lower-extremity arthroplasty: rare infection with major impact.行下肢关节置换术患者中的艰难梭菌结肠炎:罕见但影响重大的感染。
Clin Orthop Relat Res. 2013 Oct;471(10):3178-85. doi: 10.1007/s11999-013-2906-x.